業績一覧
2023年 業績
Hirohata S, Kikuchi H, Sawada T, Kuwana M, Kawachi I, Kirino Y, Ishigatsubo Y, Takeno M. Effect of infliximab on chronic progressive Behcet's disease: Influence of the timing of introduction on the patient outcome. Intern Med. 2023 Jun 21. doi: 10.2169/internalmedicine.1969-23. Online ahead of print.
Nagafuchi H, Kikuchi H, Ishibash H, Maeda H, Ogino H, Kirino Y, Sawada T, Saito K, Kuwana M, Hirohata S, Ishigatsubo Y, Niimi M, Okita Y, Miyata T, Shigematsu H, Takeno M. Recommendations for the management of the vascular involvement in Behçet's disease by the Japanese national research committee for Behçet's disease-secondary publication. Mod Rheumatol. 2023 Dec 22;34(1):182-193.
Takeuchi M, Usui Y, Namba K, Keino H, Takeuchi M, Takase H, Kamoi K, Hase K, Ito T, Nakai K, Maruyama K, Kobayashi E, Mashimo H, Sato T, Ohguro N, Hori J, Okada AA, Sonoda KH, Mizuki N, Goto H.: Ten-year follow-up of infliximab treatment for uveitis in Behçet disease patients: A multicenter retrospective study. Front Med (Lausanne) 2023 Jan 20;10:1095423. eCollection 2023.
Tomizuka T, Kikuchi H, Okubo M, Asako K, Miyata S, Kono H. Natural history of Behçet's disease focusing on remission of oral ulcers. Mod Rheumatol. 2023 Apr 13;33(3):566-573. doi: 10.1093/mr/roac035.
Teshigawara T, Meguro A, Takeuchi M, Ishido M, Soejima Y, Hirahara L, Kirino Y, Ohno S, Mizuki N. Replication Study of the Association of GAS6 and PROS1 Polymorphisms with Behçet’s Disease in a Japanese Population. Ocul Immunol Inflamm, 2023. Ocul Immunol Inflamm Feb 22:1-7
